866-997-4948(US-Canada Toll Free)

Investigation Report on China Temozolomide Market, 2010-2019

Published By :

China Research and Intelligence Co., Ltd. (CRI)

Published Date : Aug 2015

Category :

Manufacturing, Packaging & Detailing

No. of Pages : 30 Pages

Among all anti-tumor drugs, alkylating agent boasts of the longest history of application. Since nitrogen mustard was used to treat malignant lymphoma in 1942, alkylating agent has become the first-line anti-tumor drug due to its cheap price. The major varieties of alkylating agent are temozolomide and oxaliplatin. First developed by Schering-Plough, temozolomide was approved by FDA to treat glioma in 1999 and entered China since 2000.

Having efficacy in glioma, leukemia, melanoma, lymphoma and solid tumor, temozolomide can easily penetrate through blood-brain barrier and stay stable in acid environment with a broad antitumor spectrum and low toxicity. And it can be taken orally in patients who have drug resistance to nitrosoureas.

According to relevant statistics, about 60% of primary brain tumors are malignant ones. The incidence of malignant brain tumor in China is 80-100/1 million and the annual number of new cases is over 200,000. Temozolomide has reported a remarkable growth in global sales since its debut.

According to CRI

Table of Content

1 Related Concepts of Temozolomide
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Temozolomide in China
2.1 Patent and Approval Information of Temozolomide in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Temozolomide Sales in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Temozolomide Manufacturers in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Temozolomide in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Temozolomide in Chinese Hospitals in 2014
6.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd
6.2 Orion (Finland)
6.3 Shanghai Schering-Plough Pharmaceutical Co., Ltd.
6.4 Beijing SL Pharmaceutical Co., Ltd

7 Major Manufacturers of Temozolomide in Chinese Market, 2010-2014
7.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd
7.2 Orion (Finland)
7.3 Shanghai Schering-Plough Pharmaceutical Co., Ltd.
7.4 Beijing SL Pharmaceutical Co., Ltd

8 Market Outlook of Temozolomide in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

List of Table

NA

List of Chart


?Chart Approval Information of Temozolomide in China
Chart Registration Information of Temozolomide in China
Chart Temozolomide Sales in China
Chart Sales Value of Temozolomide in China, 2010-2014
Chart Sales Value of Temozolomide in Some Regions in China, 2010-2014
Chart Sales Volume of Temozolomide in China, 2010-2014
Chart Sales Volume of Temozolomide in Some Regions in China, 2010-2014
Chart Sales Value and Market Share of Temozolomide Made by Orion (Finland) in China, 2010-2014
Chart Sales Value and Market Share of Temozolomide Made by Jiangsu Tasly Diyi in China, 2010-2014
Chart Sales Value and Market Share of Temozolomide Made by Schering-Plough in China, 2010-2014
Chart Sales Value and Market Share of Temozolomide Capsule in China, 2010-2014
Chart Price of Temozolomide Made by Jiangsu Tasly Diyi in Some Chinese Cities in 2014
Chart Price of Temozolomide Made by Orion (Finland) in Some Chinese Cities in 2014
Chart Price of Temozolomide Made by Schering-Plough in Some Chinese Cities in 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *